Skip to main content
TipRanks
Go Ultimate75% OFF

InDex Pharmaceuticals Holding AB (1NP1) AI Stock Analysis

5 Followers
DE:1NP1

InDex Pharmaceuticals Holding AB

(Frankfurt:1NP1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very low leverageExceptionally low debt reduces fixed financial obligations and preserves balance-sheet flexibility while the company advances its pipeline. This provides greater capacity to absorb development setbacks or fund operations without the added pressure of significant interest-bearing leverage.
Negative Factors
Persistent cash burnOngoing negative operating and free cash flow means the business is consuming capital rather than funding development internally. If this pattern continues, InDex will remain dependent on financing, partnerships, or other funding sources to sustain clinical and regulatory activities.

InDex Pharmaceuticals Holding AB (1NP1) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:1NP1-63.33%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 103.06M
Dividend Yield
―
Average Volume (3M)
8,403
Price to Earnings (P/E)
-1.0
Beta (1Y)
0.07
Revenue Growth
-180.59%
EPS Growth
-265.58%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producin...

InDex Pharmaceuticals Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:1NP1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 360.89M1.9063.09%―――
SE:HNSASE:HNSA60NeutralSEK 4.82B-5.71――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:VICOSE:VICO44NeutralSEK 2.88B-5.23-55.97%―-54.97%-1.66%
SE:SYNACTSE:SYNACT43NeutralSEK 737.53M-6.95-60.58%――14.35%
SE:BINVSE:BINV37UnderperformSEK 142.80M-0.28-128.54%―-83.67%-50.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:1NP1SE:HNSASE:BINVSE:SYNACTSE:VICOSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:1NP1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:1NP1InDex Pharmaceuticals Holding AB1.07-1.83-63.05%
SE:HNSAHansa Biopharma45.1416.4057.06%
SE:BINVBioInvent International AB2.09-27.96-93.04%
SE:SYNACTSynAct Pharma AB13.00-8.30-38.97%
SE:VICOVicore Pharma Holding AB9.84-0.62-5.93%
SE:CANTACantargia AB1.29-1.94-60.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.